By Michael Martina BEIJING (Reuters) – A Chinese bribery investigation into British drugmaker GlaxoSmithKline has sent tremors through multinational pharmaceutical firms in China, prompting at least one to review how they do business in the country. Experts said foreign companies across the spectrum were watching closely to see what happened to GSK and its four detained Chinese executives given bribery and business go hand-in-hand in the world's second biggest economy. …
There are no comments yet. Why not be the first to speak your mind.